CY1120888T1 - Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες - Google Patents

Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες

Info

Publication number
CY1120888T1
CY1120888T1 CY181100850T CY181100850T CY1120888T1 CY 1120888 T1 CY1120888 T1 CY 1120888T1 CY 181100850 T CY181100850 T CY 181100850T CY 181100850 T CY181100850 T CY 181100850T CY 1120888 T1 CY1120888 T1 CY 1120888T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
active agents
compositions including
including active
transparent pharmaceutical
Prior art date
Application number
CY181100850T
Other languages
English (en)
Inventor
Valérie Masini-Eteve
Denis Canet
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of CY1120888T1 publication Critical patent/CY1120888T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει συνθέσεις και μεθόδους για παροχή κατακρατημένης αποδέσμευσης ενός ενεργού παράγοντα μέσα από το δέρμα ενός υποκειμένου, όπου μια φαρμακευτική διαδερματική σύνθεση περιλαμβάνει τουλάχιστον έναν εστέρα λιπαρού οξέος και μια θεραπευτικώς αποτελεσματική ποσότητα ενεργού παράγοντα.
CY181100850T 2009-10-27 2018-08-13 Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες CY1120888T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25524109P 2009-10-27 2009-10-27
EP09178762 2009-12-10
PCT/EP2010/066283 WO2011051354A2 (en) 2009-10-27 2010-10-27 Transdermal pharmaceutical compositions comprising active agents
EP10768983.8A EP2493508B1 (en) 2009-10-27 2010-10-27 Transdermal pharmaceutical compositions comprising active agents

Publications (1)

Publication Number Publication Date
CY1120888T1 true CY1120888T1 (el) 2019-12-11

Family

ID=42102488

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100850T CY1120888T1 (el) 2009-10-27 2018-08-13 Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες

Country Status (23)

Country Link
US (2) US10080760B2 (el)
EP (2) EP3360575B1 (el)
JP (1) JP5727494B2 (el)
CN (1) CN102686240B (el)
AU (1) AU2010311523B2 (el)
BR (1) BR112012010083B8 (el)
CA (1) CA2778689C (el)
CY (1) CY1120888T1 (el)
DK (2) DK2493508T3 (el)
ES (2) ES2685313T3 (el)
FI (1) FI3360575T3 (el)
HR (2) HRP20230482T1 (el)
HU (2) HUE039200T2 (el)
IL (1) IL219236A (el)
LT (2) LT3360575T (el)
PL (2) PL2493508T3 (el)
PT (2) PT3360575T (el)
RS (2) RS64190B1 (el)
RU (2) RU2639087C2 (el)
SI (2) SI3360575T1 (el)
TR (1) TR201811600T4 (el)
WO (1) WO2011051354A2 (el)
ZA (1) ZA201202855B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US20120004204A1 (en) * 2010-07-02 2012-01-05 Biosante Pharmaceuticals, Inc. Methods for treating sexual dysfunction while decreasing cardiovascular risk
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2592370C9 (ru) * 2014-04-24 2016-08-27 Иван Иванович Дедов Средство на основе дегидроэпиандростерона, способ его применения
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
EP3370178A3 (en) 2017-03-03 2018-12-19 Tata Consultancy Services Limited Method and system for in silico testing of actives on human skin
RU2751037C1 (ru) * 2020-04-03 2021-07-07 Богдан Иванович Асатуров Фармацевтическая композиция на основе аутобиокомпонентов мочи человека для трансдермального применения с лечебной или косметической целью
CN111803469B (zh) * 2020-07-15 2022-08-12 浙江海阁堂医药有限公司 一种含雌二醇透皮吸收缓释贴片及其制备方法
CN113730339B (zh) * 2021-09-17 2023-08-22 中国药科大学 一种黄体酮缓释组合物及其应用
EP4308088A4 (en) * 2021-11-08 2024-06-12 Weiyong Li TRANSDERMAL DRUG DELIVERY SYSTEM FOR DELIVERING DRUG TO A PATIENT

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1106455B (de) 1959-05-29 1961-05-10 Upjohn Co Salbengrundlage
FR2518879A1 (fr) 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH0798935B2 (ja) 1987-11-25 1995-10-25 有限会社野々川商事 品質劣化防止剤
EP0364211B1 (en) 1988-10-11 1994-12-21 Shire Holdings Ltd. A percutaneous pharmaceutical preparation
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
EP0409383B1 (en) * 1989-07-21 1994-04-06 Izhak Blank Estradiol compositions and methods for topical applications
US5232703A (en) 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
MX9101787A (es) 1990-10-29 1992-06-05 Alza Corp Formulaciones,metodos y dispositivos anticonceptivos transdermicos
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
CA2176824A1 (en) 1993-12-27 1995-07-06 Hiroshi Kuroda Percutaneously absorbable preparation
CN1106259A (zh) 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
JP3081531B2 (ja) 1996-03-22 2000-08-28 株式会社ヱビス科学研究所 手投げ消火液弾
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
RU2122396C1 (ru) 1996-07-12 1998-11-27 Валентина Александровна Андрюшина Биологически-активная добавка в косметические изделия
AU718811B2 (en) 1996-10-30 2000-04-20 Theratech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers
KR100215027B1 (ko) 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
DK1510213T3 (da) 1997-11-10 2009-03-23 Strakan Int Ltd Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron
EP1043020A1 (en) 1997-12-25 2000-10-11 Daiichi Pharmaceutical Co., Ltd. Medicinal composition for percutaneous administration
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
KR100856523B1 (ko) 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
KR100416646B1 (ko) 2000-08-14 2004-02-05 구주제약주식회사 리도카인을 함유한 조루치료용 마이크로에멀젼 하이드로겔 제형의 약학 조성물
US20040002482A1 (en) 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
FR2814074B1 (fr) 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
JP2002212105A (ja) 2001-01-22 2002-07-31 Lion Corp 水性皮膚外用剤組成物
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US20040072810A1 (en) 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
HU230920B1 (hu) * 2002-03-15 2019-03-28 Besins Healthcare Luxembourg Sarl Depresszió kezelésére szolgáló androgén gyógyászati készítmények
US6756050B2 (en) 2002-06-28 2004-06-29 Ultra Biotech Limited Dietary supplements for improving memory
FR2848112B1 (fr) 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
EP1608353B1 (en) 2003-04-01 2014-04-30 Besins Healthcare Luxembourg SARL Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US20070196325A1 (en) 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
EP1634583A1 (en) 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
AU2005293712B2 (en) * 2004-10-14 2011-04-21 Besins Healthcare Luxembourg Sarl 4-hydroxy tamoxifen gel formulations
US20070082039A1 (en) 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
CA2604400A1 (en) 2005-04-12 2006-10-19 Unimed Pharmaceuticals, Inc. Method of treating or preventing bone deterioration or osteoporosis
KR20110108426A (ko) 2005-04-25 2011-10-05 다우 파마슈티컬 사이언시즈 건선 치료를 위한 클로베타솔 분무 제형의 용도
WO2007038496A2 (en) * 2005-09-27 2007-04-05 Chemic Laboratories, Inc. Synthesis of fatty alcohol esters of hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers
EP2147674A1 (en) 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
EP3202420B1 (en) 2008-12-11 2020-03-04 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents

Also Published As

Publication number Publication date
EP3360575B1 (en) 2023-04-19
EP3360575A1 (en) 2018-08-15
CN102686240B (zh) 2015-05-27
ES2685313T3 (es) 2018-10-08
HUE062026T2 (hu) 2023-09-28
PL2493508T3 (pl) 2018-11-30
PL3360575T3 (pl) 2023-06-05
ES2945590T3 (es) 2023-07-04
AU2010311523A1 (en) 2012-05-17
RU2017131709A3 (el) 2020-10-21
FI3360575T3 (fi) 2023-05-05
AU2010311523B2 (en) 2013-10-17
JP5727494B2 (ja) 2015-06-03
ZA201202855B (en) 2013-06-26
US20110098258A1 (en) 2011-04-28
DK3360575T3 (da) 2023-05-08
US11040043B2 (en) 2021-06-22
RU2017131709A (ru) 2019-02-06
WO2011051354A3 (en) 2012-03-01
BR112012010083B8 (pt) 2021-08-31
TR201811600T4 (tr) 2018-09-21
WO2011051354A2 (en) 2011-05-05
WO2011051354A4 (en) 2012-04-26
RS64190B1 (sr) 2023-06-30
CA2778689A1 (en) 2011-05-05
US10080760B2 (en) 2018-09-25
IL219236A (en) 2016-02-29
LT2493508T (lt) 2018-10-25
CN102686240A (zh) 2012-09-19
PT3360575T (pt) 2023-05-15
PT2493508T (pt) 2018-10-09
RU2639087C2 (ru) 2017-12-19
CA2778689C (en) 2019-06-11
RU2012121708A (ru) 2013-12-10
SI3360575T1 (sl) 2023-07-31
BR112012010083B1 (pt) 2021-05-18
LT3360575T (lt) 2023-06-12
US20190160077A1 (en) 2019-05-30
EP2493508B1 (en) 2018-07-18
EP2493508A2 (en) 2012-09-05
BR112012010083A2 (pt) 2020-10-27
JP2013508444A (ja) 2013-03-07
DK2493508T3 (en) 2018-09-03
HRP20230482T1 (hr) 2023-10-27
HUE039200T2 (hu) 2018-12-28
HRP20181346T1 (hr) 2018-10-19
RS57596B1 (sr) 2018-11-30
SI2493508T1 (sl) 2018-10-30
IL219236A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1117847T1 (el) Φαρμακευτικο σκευασμα που περιλαμβανει ενα ή περισσοτερους εστερες φουμαρικου οξεος σε μητρα διαβρωσης
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
GT201200276A (es) Combinaciones de compuestos activos
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
BR112015011430A2 (pt) composição para liberação imediata e prolongada
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
FR2915683B1 (fr) Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
MX353580B (es) Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112013019924A8 (pt) Composições para cuidado oral